Work

Neoadjuvant and perioperative immunotherapy in resectable non–small cell lung cancer: Evidence to date and remaining questions

Year: 2025

Type: article

Abstract: The neoadjuvant and perioperative use of chemo-immunotherapy in resectable non–small cell lung cancer (NSCLC) has reshaped the treatment approach for locally advanced disease and has considerably improved outcomes. The addition of immune checkpoint inhibitors in the neoadjuvant (before surgery alone) and perioperative (before and after surgery) settings aims to target micrometastatic disease before resection while tumor antigens are abundant.1 To date, several landmark Phase 3 trials have demonstrated the improved outcomes, including event-free survival (EFS), overall survival (OS), pathological complete response (pCR), and major pathological response (Table 1).

Source: JTCVS Open

DOI: 10.1016/j.xjon.2025.101577

Authors: Raphael S. Werner, Nina Steinmann, Isabelle Opitz

Institutions: University Hospital Zurich, University of Zurich

Language: English

Topic: Lung Cancer Diagnosis and Treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,431